# Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma

> **NCT02733809** · PHASE4 · UNKNOWN · sponsor: **King Saud University** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02733809
- **Lead sponsor:** King Saud University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733809, "Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02733809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*